化脓性椎体骨髓炎早期转换为口服抗生素治疗(SAVE):一项开放标签、非劣效性、全国性随机对照临床试验的研究方案
SAVE试验为研究者发起的1:1随机、对照、非劣效性、平行组、开放标签试验,在丹麦感染科纳入成人化脓性椎体骨髓炎(PVO)患者,比较静脉抗生素缩短至1周是否非劣于现行丹麦国家指南。主要终点为全因死亡、脊柱相关非计划手术、原病原菌菌血症复发、培养复发及因PVO重新静脉抗生素>7天的复合终点,由盲法终点委员会裁定。
要点
- 现行丹麦指南:无并发症PVO总抗生素6周(静脉2周+口服4周),有并发症12周(静脉4周+口服8周)。
- 纳入需在适当静脉抗生素第7天时C反应蛋白(CRP)降至峰值<75%或<20 mg/l。
- 主要终点为全因死亡、脊柱相关非计划手术、原病原菌菌血症复发、培养复发及重新静脉抗生素>7天的复合终点。
核心结论
- 若早期转换为口服治疗不劣于现行丹麦国家指南,将为缩短住院时间、降低成本和提高患者自主性提供依据。
研究设计与样本
- SAVE试验为研究者发起的1:1随机、对照、非劣效性、平行组、开放标签试验。
- 在丹麦感染科纳入并评估所有诊断为PVO并接受治疗的成人患者。
- 计划纳入并随机530例患者。
主要发现
- 主要终点为全因死亡、与脊柱及PVO相关的非计划手术、原病原菌菌血症复发、从感染区域相关材料培养出初始病原菌的复发、因PVO重新给予静脉抗生素>7天的复合终点。
- 主要终点由盲法终点委员会裁定。
- 纳入排除标准包括过去24个月内PVO病史、当前PVO发作前植入脊柱植入物、其他感染灶需静脉抗生素>7天、特定细菌及真菌为病因、严重免疫抑制等。
- 患者需在适当静脉抗生素第7天时CRP降至峰值<75%或<20 mg/l方可随机。
关键数值与推荐
- 现行丹麦国家指南推荐无并发症PVO抗生素治疗6周(静脉2周后口服4周),有并发症PVO抗生素治疗12周(静脉4周后口服8周)。
- 主要终点为全因死亡、脊柱相关非计划手术、原病原菌菌血症复发、培养复发及重新静脉抗生素>7天的复合终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current Danish National Guideline (DNG) for treatment of pyogenic vertebral osteomyelitis (PVO) recommends 6 weeks antibiotic (AB) treatment, with a 2-week intravenous (IV) AB lead-in followed by 4 weeks oral AB for uncomplicated PVO, and 12 weeks AB treatment with a 4-week IV AB lead-in followed by 8 weeks oral AB for complicated PVO. The primary objective of the current study is to investigate whether shortening the duration of IV AB to one week is non-inferior to the current DNG. METHODOLOGY: The SAVE trial is an investigator initiated, randomized (1:1), controlled, non-inferiority, parallel group, open-label trial. Patients will be included at departments of infectious diseases in Denmark. All adult patients diagnosed with and treated for PVO will be assessed for eligibility. Patients will be eligible for inclusion if they fulfill all the inclusion and none of the exclusion criteria. Exclusion criteria include among others previous episodes of PVO within the past 24 months, spinal implants inserted prior to current episode of PVO, other infectious foci necessitating >7 days of IV AB, identification of selected bacteria as well as fungi as the etiology and severe immunocompromise. Patients will be randomized if their C-reactive protein (CRP) has decreased to <75% of peak value or to <20 mg/l by day 7 of appropriate IV AB. Five-hundred thirty patients will be included and randomized. The primary endpoint is a composite of all-cause mortality, unplanned surgical intervention in relation to the spine and related to PVO, relapse of bacteremia with the primary pathogen, relapse of bacteria by culture with the initial pathogen being cultured from relevant material from infected areas in relation to the spine or iliopsoas muscle (detected by culture), renewed course of IV ABs given for >7 days for treatment of PVO. The primary endpoint will be adjudicated by a blinded end-point committee. DISCUSSION: If early transition to oral therapy is found non-inferior to the current DNG, it will provide the basis for shortening hospitalization, reducing costs, and increasing patient autonomy. TRIAL REGISTRATION: European Union Clinical Trials - EU CT Number 2023-507617-96-01: First approval 27/11/2023. Link: https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-507617-96-01 .
引用
- Theilgaard ZP, Weis N, Ravn P, et al. Early shift to oral antibiotic treatment for pyogenic vertebral osteomyelitis (SAVE): study protocol for an open label, non-inferiority, nation-wide randomized controlled clinical trial. Trials. 2025. PMID: 41372803. doi:10.1186/s13063-025-09316-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。